Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: Secret_Agent_Man who wrote (3)	9/5/2000 9:33:18 PM
From: Secret_Agent_Man	Read Replies (1) \| Respond to of 332

Robbie Stephen's=BUY AtheroGenics (Nasdaq: AGIX $10.375) Buy Jay Silverman, Biopharmaceuticals "We are initiating coverage of AtheroGenics with a Buy rating," said Silverman. "The company develops small molecule drugs to combat diseases of chronic inflammation. Its vascular protectant compounds block the production of vascular cell adhesion molecules, key players in the inflammatory response." Only Chase-H+Q, AG-EDWARDS and ADAMS HARKNESS + HILL left to comment + we should've ended phase II and be moving towards phase III of 1067 if data continues to be favorable... cheers